{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:31:10Z","timestamp":1791916270633,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern Med"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies suggest an increase in autoimmune diseases following SARS\u2010CoV\u20102 infection and\/or COVID\u201019\u2010vaccination. We aimed to describe possible associations in Norway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We used information from the emergency preparedness register for COVID\u201019, BeredtC19, for all residents aged 18\u201364 (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a03,450,080). BeredtC19 includes data from mandatory nationwide registers on demographics, SARS\u2010CoV\u20102 tests, deaths, vaccinations, and hospitalizations. Cox regression was used to estimate adjusted hazard ratios (aHRs) for 30\u2010day and 30\u2013180 day risk windows.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>SARS\u2010CoV\u20102 infection was associated with an increased risk of purpura, thrombocytopenia, and agranulocytosis within 30 days and 30\u2013180 days. In the first 30 days, Bell's palsy and inflammatory arthritis were associated with infection, whereas 30\u2013180 days postinfection showed an association with polyneuropathy. Vaccination was associated with an increased risk of inflammatory bowel disease (IBD) and celiac disease, both in the first 30 days and 30\u2013180 days postvaccination. Additionally, in the first 30 days postvaccination, we found associations with inflammatory arthritis and erythema nodosum, and between 30 and 180 days with arthralgia, agranulocytosis, and acute disseminated encephalomyelitis (ADEM). There was also a reduced risk of dermatopolymyositis 30\u2013180 days postvaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Most autoimmune disorders showed no significant association with SARS\u2010CoV\u20102 infection or COVID\u201019 vaccination. Associations between vaccination and IBD and ADEM warrant further investigations, as these observations reflect associations and do not establish causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/joim.70052","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T04:44:22Z","timestamp":1764737062000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["New\u2010onset autoimmune disease following SARS\u2010CoV\u20102 infection and mRNA vaccination in Norway: A retrospective cohort study"],"prefix":"10.1111","volume":"299","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-1563","authenticated-orcid":false,"given":"H\u00e5kon","family":"B\u00f8\u00e5s","sequence":"first","affiliation":[{"name":"Department of Infection Control and Vaccines Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-2060","authenticated-orcid":false,"given":"Paz Lopez\u2010Doriga","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-9393","authenticated-orcid":false,"given":"Jesper","family":"Dahl","sequence":"additional","affiliation":[{"name":"Department of Infection Control and Vaccines Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-4449","authenticated-orcid":false,"given":"Hanne L.","family":"Gulseth","sequence":"additional","affiliation":[{"name":"Division of Public Health and Prevention Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-1183","authenticated-orcid":false,"given":"German","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15030782"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2494"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13020260"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080815"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.053"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"e_1_2_11_8_1","unstructured":"Food and Drug Administration.Vaccines and related biological products advisory committee meeting.Silver Spring:Food and Drug Administration;2020."},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13443"},{"key":"e_1_2_11_10_1","volume-title":"Immunization safety surveillance: guidelines for immunization programme managers on surveillance of adverse events following immunization","author":"World Health Organization","year":"2016"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1435"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlpt.2022.100635"},{"key":"e_1_2_11_13_1","volume-title":"Ukerapport uke 42 COVID\u201019: ukerapporter om koronavirus og covid\u201019","author":"Norwegian Institute of Public Health","year":"2020"},{"key":"e_1_2_11_14_1","volume-title":"Ukerapport uke 11 (14.03.22\u201320.03.22):Ukerapporter om koronavirus og covid\u201019","author":"Norwegian Institute of Public Health","year":"2022"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1267"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/14034948211000813"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.05.075"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36120"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101783"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1337406"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03049-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06670-0"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.017"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103811"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-17695-8"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102154"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01556-7"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068373"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02001-z"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.100"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102830"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2311969"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.04.097"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/joim.70052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T05:00:36Z","timestamp":1768021236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/joim.70052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/joim.70052"],"URL":"https:\/\/doi.org\/10.1111\/joim.70052","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"2025-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}